The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. Paxlovid is a ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury and previous problems with pill versions.

Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial.

Pfizer, which makes the Comirnaty vaccine with its German partner BioNTech, has already promised that U.S. residents who lack insurance will be covered by its own patient assistance program.

Paxlovid is an oral medication used to treat COVID-19 in high risk individuals. Medicare beneficiaries can access it at no cost through February 28, 2025, via Pfizer’s patient assistance program.

In anticipation of the IRA and expected reduction in hub, patient assistance programs, and affordability program budgets, manufacturers should be looking to streamline their patient support operations ...

Learn about the U.S. government's patient assistance programs for equitable access to COVID-19 treatment, including free oral antivirals and the role of Pfizer in providing access to treatment.

In 2023, Pfizer priced Paxlovid at $1,390 for the five-day treatment course. If your plan doesn’t cover Paxlovid or if your out-of-pocket payment is high, you may be eligible to receive assistance ...

Individuals on Medicare, Medicaid, and those who are uninsured will continue to be able to access HHS-procured Paxlovid for free through the end of 2024 via a patient-assistance program. From ...

Pfizer is implementing a “cost realignment program” expected to save the pharmaceutical giant at least $3.5 billion as it prepares for revenue drops for its Covid-19 vaccine and Paxlovid, a ...